NEWS
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Elicio Therapeutics presented updated preliminary results from the AMPLIFY-7P Phase 1 clinical trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. Key findings show mKRAS-specific T cell responses in all evaluable patients, with the 4.9 mg dose group showing 12-fold higher response than the 1.4 mg group. The magnitude of T cell response correlated with disease-free survival (DFS). T cell responses were durable up to 1.5 years, with antigen spreading detected in 100% of RP2D-treated patients. The vaccine remains safe and well-tolerated, with Phase 2 interim DFS analysis expected in H1 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2544Followers
107Following
28KVisitors
Follow